aid classic elispot plate reader (Cellular Technology Ltd)
Structured Review

Aid Classic Elispot Plate Reader, supplied by Cellular Technology Ltd, used in various techniques. Bioz Stars score: 99/100, based on 83 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elispot+plates/S6+Universal+M2/pmc12936837-401-18-23
Average 99 stars, based on 83 article reviews
Images
1) Product Images from "Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host"
Article Title: Extensive evolution and T cell escape by SARS-CoV-2 in a 2.5-year persistent infection of an immunocompromised host
Journal: iScience
doi: 10.1016/j.isci.2026.114917
Figure Legend Snippet: Magnitude and specificity of T cell memory responses generated by 899-day infection (A) Ex vivo IFNγ-ELISpot well images. DMSO control unstimulated wells and wells stimulated with overlapping peptides covering S1 and S2 region of Spike (duplicates shown), or single peptides S51 and S134. (B) Total magnitude of SARS-CoV-2-specific memory T cell response to structural proteins Spike, membrane (M), nucleoprotein (NP) and open reading frame 3a (ORF3a) and RTC proteins (NSP7, NSP12 polymerase, and NSP13 helicase) colored by protein targeted and measured after persistent infection (>900 days). (C and D) Total magnitude of SARS-CoV-2-specific T cell response (C) or T cell response to Structural and RTC proteins (D) in pre-pandemic samples (pre-August 2019), in exposed healthcare workers (HCW) who remained seronegative, including abortive infections, and in HCW with laboratory confirmed SARS-CoV-2 infections (samples 4 months post-exposure/infection in June to July 2020) for comparison to T cell response in persistently infected patient. (E) Ratio of the magnitude of the T cell response to RTC/structural T cells. Percentage of cohort with a response above 1 (stronger response to RTC than structural proteins) shown below. (F) Magnitude of T cell response to a pool of epitopes from Flu, EBV, and CMV. (B–E) Subset of data previously published in Swadling et al. (A–F) IFNγ-ELISpot. (C and D) Box and Whisker, Tukey. (C–F) Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗ p ≤ 0.01; ∗∗∗ p ≤ 0.001; ∗∗∗∗ p < 0.0001. (E and F) Bars, geomean.
Techniques Used: Generated, Infection, Ex Vivo, Enzyme-linked Immunospot, Control, Membrane, Comparison, Whisker Assay
Figure Legend Snippet: Failure of host T cells to recognize emerging virus (A) Ex vivo magnitude of the T cell response to individual ancestral sequence peptides in which mutation arose over persistent infection by IFNγ-ELISpot. (B) Magnitude of the CD4 and CD8 T cell responses after 10-day in vitro peptide expansion with individual ancestral sequence peptides. Percentage of CD4 and CD8 producing IFNγ, TNF, or both are shown. (C) Magnitude of IFNγ+, IFNγ+TNF+, and CTV lo IFNγ+ CD4 and CD8 T cells after 8-day expansion with a pool of 12 peptides corresponding to ancestral sequence epitopes or variant sequence epitopes containing mutations in the virus isolated at day 899 of infection. (D) Magnitude of the IFNγ+TNF+ CD4 or CD8 T cell response after 10-day in vitro peptide stimulation with individual epitopes using ancestral sequence or variant sequence peptides for culture and re-stimulation on day 9. Summary data showing all T cell responses that were detectable (left) or shown for individual peptides (right) for CD4 then CD8 T cells. Duplicate and triplicate stimulations are shown for CD8 T cells for M14 and NSP2, respectively. (D) Bars, mean. Statistical analysis was performed using Kruskal-Wallis tests with Dunn’s correction. ∗ p ≤ 0.05; ∗∗∗ p ≤ 0.001. Peptide sequences shown in .
Techniques Used: Virus, Ex Vivo, Sequencing, Mutagenesis, Infection, Enzyme-linked Immunospot, In Vitro, Variant Assay, Isolation
Related Articles
Enzyme-linked Immunospot:Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines. Article Snippet: Biotinylated secondary antibody and StreptavidinHRP (both Immunospot, mTNFap-2M/2) were applied, followed by Immunospot Blue Developer solution for spot development. .. Pre-coated Article Title: UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial. Article Snippet: Article Article Title: Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients Article Snippet: .. The Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines. Article Snippet: Biotinylated secondary antibody (Mabtech, 3321-6) AR TI CL E IN P RE SS and Streptavidin-HRP (Mabtech, 3310-9) were applied, followed by TMB substrate for spot development. .. Pre-coated Article Title: Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells Article Snippet: .. Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines Article Snippet: Plates were incubated for 48 h. Biotinylated secondary antibody (Mabtech, 3321-6) and Streptavidin-HRP (Mabtech, 3310-9) were applied, followed by TMB substrate for spot development. .. Pre-coated Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines Article Snippet: Plates were incubated for 24 h. Biotinylated secondary antibody and Streptavidin-HRP (both Immunospot, mTNFap-2M/2) were applied, followed by Immunospot Blue Developer solution for spot development. .. Pre-coated Blocking Assay:Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines. Article Snippet: Biotinylated secondary antibody and StreptavidinHRP (both Immunospot, mTNFap-2M/2) were applied, followed by Immunospot Blue Developer solution for spot development. .. Pre-coated Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines. Article Snippet: Biotinylated secondary antibody (Mabtech, 3321-6) AR TI CL E IN P RE SS and Streptavidin-HRP (Mabtech, 3310-9) were applied, followed by TMB substrate for spot development. .. Pre-coated Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines Article Snippet: Plates were incubated for 48 h. Biotinylated secondary antibody (Mabtech, 3321-6) and Streptavidin-HRP (Mabtech, 3310-9) were applied, followed by TMB substrate for spot development. .. Pre-coated Article Title: A binary self-amplifying expression platform enabling lipid nanoparticle-free vaccines and nanomedicines Article Snippet: Plates were incubated for 24 h. Biotinylated secondary antibody and Streptavidin-HRP (both Immunospot, mTNFap-2M/2) were applied, followed by Immunospot Blue Developer solution for spot development. .. Pre-coated other:Article Title: Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer. Article Snippet: Meriem Belabed , Matthew D. Park, Cédric M. Blouin , Sreekumar Balan , Chang Y.. Moon, Grace Freed, Miguel Quijada-Álamo, Ante Peros, Raphaël Mattiuz , Amanda M. Reid, Nader Yatim, Jesse Boumelha, Camillia S. Azimi, Nelson M. LaMarche, Leanna Troncoso , Angelo Amabile, Jessica Le Berichel, Steven T. Chen, C. Matthias Wilk , Brian D. Brown , Kristen J. Radford , Sourav Ghosh , Carla V. Rothlin , Laurent Yvan-Charvet , Thomas U. Marron , Daniel J. Puleston , Elvin Wagenblast , Nina Bhardwaj , Christophe Lamaze & Miriam Merad Polymer:Article Title: UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial. Article Snippet: Article Software:Article Title: Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients Article Snippet: .. The Article Title: Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells Article Snippet: .. |
